Antidiabetic drugs and the risk of cancer: beneficial, neutral, or detrimental?

[1] Asiimwe D, Mauti GO, Kiconco R. Prevalence and risk factors associated with type 2 diabetes in elderly patients aged 45–80 years in Kanungu district. J Diabetes Res. 2020; 2020: 5152146. AsiimweD MautiGO KiconcoR Prevalence and risk factors associated with type 2 diabetes in elderly patients aged 45–80 years in Kanungu district J Diabetes Res 2020 2020 5152146 10.1155/2020/5152146 Search in Google Scholar

[2] American Diabetes Association (ADA), “Classification and diagnosis of diabetes: standards of medical care in diabetes,” Diabetes Care. 2019; 42, (5): 13–28. American Diabetes Association (ADA) “Classification and diagnosis of diabetes: standards of medical care in diabetes,” Diabetes Care 2019 42 5 13 28 10.2337/dc19-S002 Search in Google Scholar

[3] World Health Organization (WHO). Classification of diabetes mellitus. WHO. 2019; pp8. World Health Organization (WHO) Classification of diabetes mellitus WHO 2019 8 Search in Google Scholar

[4] Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045. Diabetes Res Clin Pract. 2019. 2019: 107843. SaeediP PetersohnI SalpeaP MalandaB KarurangaS UnwinN Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045 Diabetes Res Clin Pract 2019 2019 107843 10.1016/j.diabres.2019.10784331518657 Search in Google Scholar

[5] Liu, YC., Nguyen, PA., Humayun, A., Chien, SC., Yang, HC.et al.). Does long-term use of antidiabetic drugs changes cancer risk? Medicine, 2019; 98(40), e17461. LiuYC. NguyenPA. HumayunA. ChienSC. YangHC Does long-term use of antidiabetic drugs changes cancer risk? Medicine 2019 98 40 e17461 10.1097/MD.0000000000017461678324431577776 Search in Google Scholar

[6] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. Cancer. 2019; 69(1): 7–34. SiegelRL MillerKD JemalA Cancer statistics, 2019 Cancer 2019 69 1 7 34 10.3322/caac.2155130620402 Search in Google Scholar

[7] Abudawood M. Diabetes and cacer- a comprehensive review. J Res Med Sci. 2019; 24:94. AbudawoodM Diabetes and cacer- a comprehensive review J Res Med Sci. 2019 24 94 10.4103/jrms.JRMS_242_19685654431741666 Search in Google Scholar

[8] Bailey CJ. The Current Drug Treatment Landscape for Diabetes and Perspectives for the Future. Clin Pharmacol Ther. 2015;98(2):170–184. BaileyCJ The Current Drug Treatment Landscape for Diabetes and Perspectives for the Future Clin Pharmacol Ther 2015 98 2 170 184 10.1002/cpt.14425963904 Search in Google Scholar

[9] Turner LW, Nartey D, Stafford RS, Singh S, Alexander GC. Ambulatory treatment of type 2 diabetes in the U.S., 1997–2012. Diabetes Care. 2014; 37(4):985–92 TurnerLW NarteyD StaffordRS SinghS AlexanderGC Ambulatory treatment of type 2 diabetes in the U.S., 1997–2012 Diabetes Care 2014 37 4 985 92 10.2337/dc13-2097417832524198301 Search in Google Scholar

[10] Steven H, Barag DO. Insulin therapy for management of type 2 diabetes mellitus: strategies for initiation and long term patient adherence. J Am Osteopath Assoc. 2011; 111: S3–S11. StevenH BaragDO Insulin therapy for management of type 2 diabetes mellitus: strategies for initiation and long term patient adherence J Am Osteopath Assoc. 2011 111 S3 S11 Search in Google Scholar

[11] Pollak M. The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer. 2012; 12(3): 159–169. PollakM The insulin and insulin-like growth factor receptor family in neoplasia: an update Nat Rev Cancer 2012 12 3 159 169 10.1038/nrc321522337149 Search in Google Scholar

[12] Mannucci E. Insulin therapy and cancer in type 2 diabetes. Int Sch Ret Notices. 2012; 2012: 240634. MannucciE Insulin therapy and cancer in type 2 diabetes Int Sch Ret Notices 2012 2012 240634 10.5402/2012/240634350437123209929 Search in Google Scholar

[13] Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R. Diabetes and cancer. Endocrine-Related Cancer. 2009; 16(4): 1103–1123. VigneriP FrascaF SciaccaL PandiniG VigneriR Diabetes and cancer Endocrine-Related Cancer 2009 16 4 1103 1123 10.1677/ERC-09-008719620249 Search in Google Scholar

[14] Yang YX, Hennessy S, Lewis JD. Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients. Gastroenterology 2004; 127(4): 1044–1050. YangYX HennessyS LewisJD Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients Gastroenterology 2004 127 4 1044 1050 10.1053/j.gastro.2004.07.01115480982 Search in Google Scholar

[15] Jonasson JM, Ljung R, Talbäck M, Haglund N, Gudbjörnsdòttir S, Steineck J. Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden. Diabetologia,. 2009; 52(9): 1745–1754. JonassonJM LjungR TalbäckM HaglundN GudbjörnsdòttirS SteineckJ Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden Diabetologia 2009 52 9 1745 1754 10.1007/s00125-009-1444-219588120 Search in Google Scholar

[16] Yang X, Ko GTC, So W. Associations of hyperglycemia and insulin usage with the risk of cancer in type 2 diabetes: the Hong Kong diabetes registry. Diabetes. 2010; 59(5): 1254–1260. YangX KoGTC SoW Associations of hyperglycemia and insulin usage with the risk of cancer in type 2 diabetes: the Hong Kong diabetes registry Diabetes 2010 59 5 1254 1260 10.2337/db09-1371285790620185812 Search in Google Scholar

[17] ORIGIN Trial Investigators, Gerstein HC, Bosch J. Basal insulin and cardiovascular and other outcomes in dysglycemia. The New England Journal of Medicine. 2012; 367(4): 319–328. ORIGIN Trial Investigators GersteinHC BoschJ Basal insulin and cardiovascular and other outcomes in dysglycemia The New England Journal of Medicine 2012 367 4 319 328 10.1056/NEJMoa120385822686416 Search in Google Scholar

[18] Staiger K, Hennige AM, Staiger H, Häring HU, Kellerer M. Comparison of the mitogenic potency of regular human insulin and its analogue glargine in normal and transformed human breast epithelial cells. Hormone and Metabolic Research. 2007; 39(1): 65–67. StaigerK HennigeAM StaigerH HäringHU KellererM Comparison of the mitogenic potency of regular human insulin and its analogue glargine in normal and transformed human breast epithelial cells Hormone and Metabolic Research 2007 39 1 65 67 10.1055/s-2007-95735217226117 Search in Google Scholar

[19] Morden NE, Liu SK, Smith J, Mackenzie TM, Skinner J, Korc M. Further exploration of the relationship between insulin glargine and incident cancer: a retrospective cohort study of older Medicare patients. Diabetes Care. 2011; 34(9): 1965–1971 MordenNE LiuSK SmithJ MackenzieTM SkinnerJ KorcM Further exploration of the relationship between insulin glargine and incident cancer: a retrospective cohort study of older Medicare patients Diabetes Care 2011 34 9 1965 1971 10.2337/dc11-0699316126321775752 Search in Google Scholar

[20] Wang GS, Hoyte C. Review of biguanides (metformin) toxicity. J Intensive Care Med. 2018; 34(11): 1177. WangGS HoyteC Review of biguanides (metformin) toxicity J Intensive Care Med 2018 34 11 1177 10.1177/088506661879338530126348 Search in Google Scholar

[21] American Diabetes Association. Prevention or delay of type 2 diabetes: standards of medical care in diabetes. Diabetes Care. 2019; 42 (Suppl.1): 529–533. American Diabetes Association Prevention or delay of type 2 diabetes: standards of medical care in diabetes Diabetes Care 2019 42 Suppl.1 529 533 Search in Google Scholar

[22] Hotta N. A new perspective on the biguanides, metformin therapy in type 2 diabetes and lactic acidosis. J Diabetes Investig. 2019; 10(4): 906–908. HottaN A new perspective on the biguanides, metformin therapy in type 2 diabetes and lactic acidosis J Diabetes Investig 2019 10 4 906 908 10.1111/jdi.13090662696031152685 Search in Google Scholar

[23] Hawley SA, Ross FA, Chevtzoff C. Use of cells expressing gamma subunit variants to identify diverse mechanisms of AMPK activation. Cell Metab. 2010; 11:554–65. HawleySA RossFA ChevtzoffC Use of cells expressing gamma subunit variants to identify diverse mechanisms of AMPK activation Cell Metab 2010 11 554 65 10.1016/j.cmet.2010.04.001293596520519126 Search in Google Scholar

[24] Pollak M. Metformin and other biguanides in oncology: advancing the research agenda. Cancer Prev Res. 2010; 3(9): 1158. PollakM Metformin and other biguanides in oncology: advancing the research agenda Cancer Prev Res. 2010 3 9 1158 10.1158/1940-6207.CAPR-10-0175295441220810670 Search in Google Scholar

[25] Algire C, Zakikhani M, Blouin M-J, Shuai JH, Pollak M. Metformin attenuates the stimulatory effect of a high energy diet on in vivo H59 carcinoma growth. Endocr Relat Cancer. 2008; 15:833–839. AlgireC ZakikhaniM BlouinM-J ShuaiJH PollakM Metformin attenuates the stimulatory effect of a high energy diet on in vivo H59 carcinoma growth Endocr Relat Cancer. 2008 15 833 839 10.1677/ERC-08-003818469156 Search in Google Scholar

[26] Bodmer M, Meier C, Krahenbuhl S, Jick SS, Meier CR, Meier CR. Long term metformin use is associated with decreased risk of breast cancer. Diabetes Care. 2010; 33:1304–8. BodmerM MeierC KrahenbuhlS JickSS MeierCR MeierCR Long term metformin use is associated with decreased risk of breast cancer Diabetes Care 2010 33 1304 8 10.2337/dc09-1791287544420299480 Search in Google Scholar

[27] Multhoff G, Molls M, Radons J. Chronic inflammation in cancer development. Front Immunol. 2011; 2: 98. MulthoffG MollsM RadonsJ Chronic inflammation in cancer development Front Immunol 2011 2 98 10.3389/fimmu.2011.00098334234822566887 Search in Google Scholar

[28] Polak M. Potential application of biguanides in oncology. J Clin Invest. 2013; 2013: 167232. PolakM Potential application of biguanides in oncology J Clin Invest 2013 2013 167232 10.1172/JCI67232375425023999444 Search in Google Scholar

[29] Zong WX, Ditsworth D, Bauer DE, Wang ZQ, Thompson CB. Alkylating DNA damage stimulates a regulated form of necrotic cell death. Genes Dev. 2004;18(11):1272–1282. ZongWX DitsworthD BauerDE WangZQ ThompsonCB Alkylating DNA damage stimulates a regulated form of necrotic cell death Genes Dev. 2004 18 11 1272 1282 10.1101/gad.119990442035315145826 Search in Google Scholar

[30] Bonanni B. Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial. J Clin Oncol. 2012;30(21):2593–2600. BonanniB Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial J Clin Oncol. 2012 30 21 2593 2600 10.1200/JCO.2011.39.376922564993 Search in Google Scholar

[31] Hosono K. Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial. Cancer Prev Res. 2010;3(9):1077–1083. HosonoK Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial Cancer Prev Res. 2010 3 9 1077 1083 10.1158/1940-6207.CAPR-10-018620810669 Search in Google Scholar

[32] Martin MJ, Hayward R, Viros A, Marais R. Metformin accelerates the growth of BRAF V600E-driven melanoma by upregulating VEGF-A. Cancer Discov. 2012;2(4):344–355. MartinMJ HaywardR VirosA MaraisR Metformin accelerates the growth of BRAF V600E-driven melanoma by upregulating VEGF-A Cancer Discov. 2012 2 4 344 355 10.1158/2159-8290.CD-11-0280336471022576211 Search in Google Scholar

[33] Seino S. Cell signalling in insulin secretion: the molecular targets of ATP, cAMP and sulfonylurea. Diabetologia. 2012; 55 (8): 2096–2108 SeinoS Cell signalling in insulin secretion: the molecular targets of ATP, cAMP and sulfonylurea Diabetologia 2012 55 8 2096 2108 10.1007/s00125-012-2562-922555472 Search in Google Scholar

[34] Proks P, Reimann F, Green N, Gribble F, Ashcroft F. Sulfonylurea stimulation of insulin secretion. Diabetes. 2002; 51 (Suppl 3): S368–376. ProksP ReimannF GreenN GribbleF AshcroftF Sulfonylurea stimulation of insulin secretion Diabetes 2002 51 Suppl 3 S368 376 10.2337/diabetes.51.2007.S36812475777 Search in Google Scholar

[35] Núñez M, Medina V, Cricco G, Croci M, Cocca C, Rivera E et al. Glibenclamide inhibits cell growth by inducing G0/G1 arrest in the human breast cancer cell line MDA-MB-231. BMC Pharmacol Toxicol. 2013; 14(1):6 NúñezM MedinaV CriccoG CrociM CoccaC RiveraE Glibenclamide inhibits cell growth by inducing G0/G1 arrest in the human breast cancer cell line MDA-MB-231 BMC Pharmacol Toxicol 2013 14 1 6 10.1186/2050-6511-14-6355838623311706 Search in Google Scholar

[36] Ardehali H, O’Rourke B. Mitochondrial K(ATP) channels in cell survival and death. J Mol Cell Cardiol. 2005; 39(1):7–16 ArdehaliH O’RourkeB Mitochondrial K(ATP) channels in cell survival and death J Mol Cell Cardiol 2005 39 1 7 16 10.1016/j.yjmcc.2004.12.003269253415978901 Search in Google Scholar

[37] Qian X, Li J, Ding J, Wang Z, Duan L, Hu G. Glibenclamide exerts an antitumor activity through reactive oxygen species-c-jun NH2-terminal kinase pathway in human gastric cancer cell line MGC-803. Biochem Pharmacol. 2008; 76(12):1705–15 QianX LiJ DingJ WangZ DuanL HuG Glibenclamide exerts an antitumor activity through reactive oxygen species-c-jun NH2-terminal kinase pathway in human gastric cancer cell line MGC-803 Biochem Pharmacol 2008 76 12 1705 15 10.1016/j.bcp.2008.09.00918840412 Search in Google Scholar

[38] Pasello G, Urso L, Conte P, Favarreto. Effects of sulphonylureas on tumor growth: a eview of the literature. Oncologist. 2013; 18(10):118–1125. PaselloG UrsoL ConteP Favarreto Effects of sulphonylureas on tumor growth: a eview of the literature Oncologist 2013 18 10 118 1125 10.1634/theoncologist.2013-0177380515424043597 Search in Google Scholar

[39] Pan HZ, Chang D, Feng LG, Xu FJ, Kuang HY, Lu MJ. Oxidative damage to DNA and its relationship with diabetic complications. Biomed Environ Sci. 2007; 20(2):160–3. PanHZ ChangD FengLG XuFJ KuangHY LuMJ Oxidative damage to DNA and its relationship with diabetic complications Biomed Environ Sci 2007 20 2 160 3 Search in Google Scholar

[40] Sliwinska A, Sliwinski T, Kasznicki J, Drzewoski J. Effect of gliclazide on nucleotide excision repair (NER) and non-homologous DNA end joining (NHEJ) in normal and cancer cells. J Physiol Pharmacol. 2010; 61(3):347–53. SliwinskaA SliwinskiT KasznickiJ DrzewoskiJ Effect of gliclazide on nucleotide excision repair (NER) and non-homologous DNA end joining (NHEJ) in normal and cancer cells J Physiol Pharmacol. 2010 61 3 347 53 Search in Google Scholar

[41] Ferruzzi P, Ceni E, Tarocchi M, Grappone C, Milani S, Galli A et al. Thiazolidiediones inhibit the growth and invasiveness of adrenocortical cancer cell line H295R. J Clin Endocrinol Metab. 2005; 19(3): 1332–1339. FerruzziP CeniE TarocchiM GrapponeC MilaniS GalliA Thiazolidiediones inhibit the growth and invasiveness of adrenocortical cancer cell line H295R J Clin Endocrinol Metab. 2005 19 3 1332 1339 10.1210/jc.2004-097815585569 Search in Google Scholar

[42] Blanquicett C, Roman J, Hart CM. Thiazolidinediones as anti-cancer agents. Cancer Ther. 2008; 6(A): 25–34. BlanquicettC RomanJ HartCM Thiazolidinediones as anti-cancer agents Cancer Ther 2008 6 A 25 34 Search in Google Scholar

[43] Vignati S, Albertini V, Rinaldi A, Kwee I, Riva C, Oldrini R et al. Cellular and molecular consequences of peroxisome proliferator-activated receptor-gamma activation in ovarian cancer cells. Neoplasia. 2006; 8(10):851–61. VignatiS AlbertiniV RinaldiA KweeI RivaC OldriniR Cellular and molecular consequences of peroxisome proliferator-activated receptor-gamma activation in ovarian cancer cells Neoplasia 2006 8 10 851 61 10.1593/neo.06433171592417032502 Search in Google Scholar

[44] Clay CE, Namen AM, Atsumi G, Willingham MC, High KP, Kute TE et al. Influence of J series prostaglandins on apoptosis and tumorigenesis of breast cancer cells. Carcinogenesis. 1999; 20(10):1905–11 ClayCE NamenAM AtsumiG WillinghamMC HighKP KuteTE Influence of J series prostaglandins on apoptosis and tumorigenesis of breast cancer cells Carcinogenesis 1999 20 10 1905 11 10.1093/carcin/20.10.190510506103 Search in Google Scholar

[45] Yang B, Lin P, Carrick KM, McNulty JA, Clifton LG, Winegar DA et al. PPARgamma agonists diminish serum VEGF elevation in diet-induced insulin resistant SD rats and ZDF rats. Biochem Biophys Res Commun. 2005; 334(1):176–82 YangB LinP CarrickKM McNultyJA CliftonLG WinegarDA PPARgamma agonists diminish serum VEGF elevation in diet-induced insulin resistant SD rats and ZDF rats Biochem Biophys Res Commun 2005 334 1 176 82 10.1016/j.bbrc.2005.06.07815993383 Search in Google Scholar

[46] Monami M, Dicembrini I, Mannucci E. Thiazolidinediones and cancers: reults of a meta-analysis of randomized clinical trials. Acta Diabetol. 2014; 51(1): 91–101. MonamiM DicembriniI MannucciE Thiazolidinediones and cancers: reults of a meta-analysis of randomized clinical trials Acta Diabetol 2014 51 1 91 101 10.1007/s00592-013-0504-823851465 Search in Google Scholar

[47] Lewis J. D., Ferrara A., Peng T. et al. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care. 2011; 34 (4): 916–922. LewisJ. D. FerraraA. PengT. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study Diabetes Care 2011 34 4 916 922 10.2337/dc10-1068306405121447663 Search in Google Scholar

[48] Hsiao F.-Y., Hsieh P.-H., Huang W.-F., Tsai Y.-W., Gau C.-S. Risk of bladder cancer in diabetic patients treated with rosiglitazone or pioglitazone: A Nested Case-control Study. Drug Safety. 2013; 36(8):b643–649. HsiaoF.-Y. HsiehP.-H. HuangW.-F. TsaiY.-W. GauC.-S Risk of bladder cancer in diabetic patients treated with rosiglitazone or pioglitazone: A Nested Case-control Study Drug Safety 2013 36 8 b643 649 10.1007/s40264-013-0080-4 Search in Google Scholar

[49] Chiu M, McBeth L, Sindhwani P, Hinds TD. Deciphering the roles of thiazolidinediones and PPARγ in bladder cancer. PPAR Res. 2017; 2017: 4810672. ChiuM McBethL SindhwaniP HindsTD Deciphering the roles of thiazolidinediones and PPARγ in bladder cancer PPAR Res 2017 2017 4810672 10.1155/2017/4810672 Search in Google Scholar

[50] Bellomo DA, Stefanelli G, Laviola L, Giorgino R, Giorgino F. Nateglinide provides tither glycemic control than glyburide in patients with type 2 diabetes with prevalent postprandial hyperglycemia. Diabet Med, 2011; 28(5): 560–65. BellomoDA StefanelliG LaviolaL GiorginoR GiorginoF Nateglinide provides tither glycemic control than glyburide in patients with type 2 diabetes with prevalent postprandial hyperglycemia Diabet Med 2011 28 5 560 65 10.1111/j.1464-5491.2010.03219.x Search in Google Scholar

[51] Blicklé JF. Meglitinide analogues: a review of clinical data focused on recent trials”. Diabetes Metab. 2006; 32 (2): 113–20 BlickléJF Meglitinide analogues: a review of clinical data focused on recent trials Diabetes Metab 2006 32 2 113 20 10.1016/S1262-3636(07)70257-4 Search in Google Scholar

[52] Chang CH, Lin JW, Wu LC, Lai MS, Chuang LM. Oral insulin secretagogues, insulin, and cancer risk in type 2 diabetes mellitus. J Clin Endocrinol Metab. 2012; 97(7):E1170–5. ChangCH LinJW WuLC LaiMS ChuangLM Oral insulin secretagogues, insulin, and cancer risk in type 2 diabetes mellitus J Clin Endocrinol Metab 2012 97 7 E1170 5 10.1210/jc.2012-116222563104 Search in Google Scholar

[53] Li D, Yeung SJ, Hassan MM, Konopleva M, Abruzesse JL. Anti-diabetic therapies affect the risk of pancreatic cancer. Gastroenetrology. 2009; 137(2): 482–488. LiD YeungSJ HassanMM KonoplevaM AbruzesseJL Anti-diabetic therapies affect the risk of pancreatic cancer Gastroenetrology 2009 137 2 482 488 10.1053/j.gastro.2009.04.013273509319375425 Search in Google Scholar

[54] McIntosh, C; Demuth, H; Pospisilik, J; Pederson, R (). Dipeptidyl peptidase IV inhibitors: How do they work as new antidiabetic agents?. Regulatory Peptides. 2005; 128 (2): 159–65. McIntoshC DemuthH PospisilikJ PedersonR Dipeptidyl peptidase IV inhibitors: How do they work as new antidiabetic agents? Regulatory Peptides 2005 128 2 159 65 10.1016/j.regpep.2004.06.00115780435 Search in Google Scholar

[55] Overbeek JA, Bakker M, van der Heijden AAW, van Herk-Sukel MPP, Herings RMC, Nijpels G. Risk of dipeptidyl peptidase-4 (DPP-4) inhibitors on site-specific cancer: A systematic review and meta-analysis. Diabetes Metab Res Rev. 2018; 34(5):e3004 OverbeekJA BakkerM van der HeijdenAAW van Herk-SukelMPP HeringsRMC NijpelsG Risk of dipeptidyl peptidase-4 (DPP-4) inhibitors on site-specific cancer: A systematic review and meta-analysis Diabetes Metab Res Rev 2018 34 5 e3004 10.1002/dmrr.300429573125 Search in Google Scholar

[56] Urasaki Y, Ohnuma K, Morimoto C, Dang N. The role of CD26/dipeptidyl peptidase IV in cancer. Front Biosci. 2008;13:1634–1645. UrasakiY OhnumaK MorimotoC DangN The role of CD26/dipeptidyl peptidase IV in cancer Front Biosci 2008 13 1634 1645 10.2741/278717981655 Search in Google Scholar

[57] Bishnoi R, Hong Y, Shah C, Azka A, Skelton WP, Huo J. et al. Dipeptidyl peptidase 4 inhibitors as novel agents in improving survival in diabetic patients with colorectal cancer and lung cancer: A Surveillance Epidemiology and Endpoint Research Medicare study. Cancer Med. 2019; 8(8): 3918–3927. BishnoiR HongY ShahC AzkaA SkeltonWP HuoJ Dipeptidyl peptidase 4 inhibitors as novel agents in improving survival in diabetic patients with colorectal cancer and lung cancer: A Surveillance Epidemiology and Endpoint Research Medicare study Cancer Med 2019 8 8 3918 3927 10.1002/cam4.2278663918731124302 Search in Google Scholar

[58] Hinnen D. Glucagon-like 1 peptides receptor for type 2 diabetes. Diabetes spectrum. 2017; 30(3): 202–210. HinnenD Glucagon-like 1 peptides receptor for type 2 diabetes Diabetes spectrum 2017 30 3 202 210 10.2337/ds16-0026 Search in Google Scholar

[59] Bjerre Knudsen L, Madsen LW, Andersen S. Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology. 2010; 151 (4): 1473–1486. Bjerre KnudsenL MadsenLW AndersenS Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation Endocrinology 2010 151 4 1473 1486 10.1210/en.2009-1272 Search in Google Scholar

[60] Chalmer T, Almdal TP, Vilsbøll T, Knop FP. Adverse drug reactions associated with the use of liraglutide in patients with type 2 diabetes – focus on pancreatitis and pancreas cancer. Expert Opinion on Drug Safety. 2015; 14(1): 171–180. ChalmerT AlmdalTP VilsbøllT KnopFP Adverse drug reactions associated with the use of liraglutide in patients with type 2 diabetes – focus on pancreatitis and pancreas cancer Expert Opinion on Drug Safety 2015 14 1 171 180 10.1517/14740338.2015.975205 Search in Google Scholar

[61] Liu Y, Zhang X, Chao S, Zhao X, Ji L. Risk of Malignant Neoplasia with Glucagon-Like Peptide-1 Receptor Agonist Treatment in Patients with Type 2 Diabetes: A Meta-Analysis. J Diabetes Res. 2019; 2019: 1534365. LiuY ZhangX ChaoS ZhaoX JiL Risk of Malignant Neoplasia with Glucagon-Like Peptide-1 Receptor Agonist Treatment in Patients with Type 2 Diabetes: A Meta-Analysis J Diabetes Res 2019 2019 1534365 10.1155/2019/1534365 Search in Google Scholar

[62] Dicembrini I, Nreu B, Mannucci E, Monami M. Sodium-Glucose Co-Transporter-2 (SGLT-2) Inhibitors and Cancer: A Meta-Analysis of Randomized Controlled Trials. Diabetes Obes Metab 2019; 21(8)1871–1877. DicembriniI NreuB MannucciE MonamiM Sodium-Glucose Co-Transporter-2 (SGLT-2) Inhibitors and Cancer: A Meta-Analysis of Randomized Controlled Trials Diabetes Obes Metab 2019 21 8 1871 1877 10.1111/dom.13745 Search in Google Scholar

[63] Nasiri AI, Rodrigues MI, Li Z, Leitner BP, Perry RJ. SGLT2 inhibition slows tumor growth in mice by reversing hyperinsulinemia. Cancer Metab. 2019; 7: 10. NasiriAI RodriguesMI LiZ LeitnerBP PerryRJ SGLT2 inhibition slows tumor growth in mice by reversing hyperinsulinemia Cancer Metab. 2019 7 10 10.1186/s40170-019-0203-1 Search in Google Scholar

[64] Komatsu S, Nomiyama T, Numata T, Kawanami T, Hamaguchi Y, Tanaka T et al. SGLT2 Inhibitor Ipragliflozin Induces Breast Cancer Apoptosis via Membrane Hyperpolarization and Mitochondria Dysfunction. Diabetes. 2018; 67 (Suppl 1): 255 KomatsuS NomiyamaT NumataT KawanamiT HamaguchiY TanakaT SGLT2 Inhibitor Ipragliflozin Induces Breast Cancer Apoptosis via Membrane Hyperpolarization and Mitochondria Dysfunction Diabetes 2018 67 Suppl 1 255 10.2337/db18-255-OR Search in Google Scholar

[65] Zhao Y, Wang Y, Lou H, Shan L. Alpha-glucosidase inhibitors and risk of cancer in patients with diabetes mellitus: a systematic review and meta-analysis. Oncotarget. 2017; 8(46): 81027–81039. ZhaoY WangY LouH ShanL Alpha-glucosidase inhibitors and risk of cancer in patients with diabetes mellitus: a systematic review and meta-analysis Oncotarget 2017 8 46 81027 81039 10.18632/oncotarget.17515 Search in Google Scholar

[66] Inoue I, Takahashi K, Noji S, Awata T, Negishi K, Katayama S. Acarbose controls postprandial hyperproinsulinemia in non-insulin dependent diabetes mellitus. Diabetes Res Clin Pract. 1997; 36(3):143–5 InoueI TakahashiK NojiS AwataT NegishiK KatayamaS Acarbose controls postprandial hyperproinsulinemia in non-insulin dependent diabetes mellitus Diabetes Res Clin Pract 1997 36 3 143 5 10.1016/S0168-8227(97)00045-4 Search in Google Scholar